Is Beyond Air, Inc. (XAIR) a Buy, Sell, or Hold?
Beyond Air, Inc.
NASDAQ:XAIR
$5.77 USD
-$1.72 (-22.96%)
- Volume
- 108.24K
- Average Volume
- 332.74K
- Market Capitalization
- $3.66M
- P/E Ratio
- -0.07
- Dividend Yield
- 0.00%
- Price Target
- $1.00
- Year High
- $95.60
- Year Low
- $5.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.80
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Amir Avniel |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | XAIR |
| CUSIP | 08862L301 |
| CIK | 0001641631 |
| Web | https://www.beyondair.net |
| Phone | 516 665 8200 |
| Currency | USD |
| Employees | 54 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 3.82 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.80 |
| Quick Ratio | 3.59 |
| Cash Ratio | 1.04 |
Sales & Book Value
| Annual Sales | $7.68M |
| Price / Sales | 0.48 |
| Cash Flow | -46.19 |
| Price / Cash Flow | -0.19 |
| Price / Book | 0.39 |
Price Target and Rating
| Average Stock Price Forecast | $1.00 |
| High Stock Price Forecast | $1.00 |
| Low Stock Price Forecast | $1.00 |
| Forecast Upside/Downside | 477.00% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-80.2 |
| Trailing P/E Ratio | -0.07 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-33.25M |
| Net Margin | -432.99% |
| Pretax Margin | -447.12% |
| Return on Equity | -360.45% |
| Return on Assets | -93.96% |
Financials Score
| AltmanZ Score | -14.42 |
| Piotroski Score | 4.00 |
| Working Capital | 18.26M |
| Total Assets | 35.38M |
| Ebit | -28.86M |
| Market Cap | 3.9M |
| Total Liabilities | 29.18M |
Poll Results
About Beyond Air, Inc. (NASDAQ:XAIR) Stock
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. ... Its headquarters are situated in Garden City, New York.
Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript
2026-06-26 11:42:09
Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript
2026-06-26 07:00:00
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026
Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast
2026-06-22 16:01:00
GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2026 on Friday, June 26, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time (ET) the same day.
2026-06-10 08:00:00
Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included below to request additional copies GARDEN CITY, N.Y.
2026-06-10 08:00:00
Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p. m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included below to request additional copies GARDEN CITY, N.
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
2026-06-01 08:00:00
GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the Nasdaq Stock Market LLC's (“Nasdaq” or the “Exchange”) Listing Rule 5550(a)(2) (the “Bid Price Rule”) by July 31, 2026.
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
2026-04-20 08:00:00
Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
2026-04-15 08:00:00
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York.
Frequently Asked Questions
-
What is the current Beyond Air, Inc. (XAIR) stock price?
-
Beyond Air, Inc.(NASDAQ:XAIR) stock price is $5.77 in the last trading session. During the trading session, XAIR stock reached the peak price of $95.6 while $5.3 was the lowest point it dropped to. The percentage change in XAIR stock occurred in the recent session was --22.96% while the dollar amount for the price change in XAIR stock was -$-1.72.
-
XAIR's industry and sector of operation?
-
The NASDAQ listed XAIR is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of XAIR?
-
Robert Scott Goodman | CEO & Director
Andrew R. Colin | Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board
Adam Newman | Corporate Secretary
Daniel J. Moorhead | Chief Financial Officer
John Jett | Head of Research & Clinical Development -
How many employees does XAIR have?
-
Number of XAIR employees currently stands at 54. XAIR operates from 900 Stewart Avenue, Garden City, NY 11530, US.
-
Link for XAIR official website?
-
Official Website of XAIR is: https://www.beyondair.net
-
How do I contact XAIR?
-
XAIR could be contacted at phone #516 665 8200 and can also be accessed through its website. XAIR operates from 900 Stewart Avenue, Garden City, NY 11530, US.
-
How many shares of XAIR are traded daily?
-
The average number of XAIR shares traded daily for last 3 months was 332.74K.
-
What is the market cap of XAIR currently?
-
The market value of XAIR currently stands at $3.66M with its latest stock price at $5.77